Latest peptide news & research

A Micropeptide that Inhibits Vascular Calcification via PKM2 Degradation

Researchers have identified a micropeptide capable of inhibiting vascular calcification by targeting PKM2 degradation, offering a novel therapeutic avenue for one of aging's most consequential cardiovascular processes. Vascular calcification, which proceeds independently of atherosclerosis, contributes to arterial stiffening and significantly elevates the risk of heart attack and stroke. This finding positions micropeptides as emerging candidates in the effort to address age-related vascular dysfunction at a mechanistic level.

Your Genes May Predict How Your Body Reacts To GLP-1s, New Study Says

A new study suggests that genetic variation may significantly influence how individuals respond to GLP-1 receptor agonists, including both weight loss outcomes and side effect profiles. The findings point toward a future of more personalized prescribing practices for GLP-1 based therapies. Clinicians and researchers are increasingly interested in pharmacogenomic factors that could optimize patient selection and treatment protocols.

GLP-1

STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices

The FDA has finalized its guidance on prescription drug use-related software, a development welcomed broadly across the pharmaceutical industry. The edition also highlights the expanding role of telehealth platforms in prescribing GLP-1 receptor agonists for addiction treatment, signaling a notable shift in how these therapies reach patients. The convergence of digital health tools and GLP-1 prescribing practices has meaningful implications for access, oversight, and clinical standards.

GLP-1

STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction

Telehealth platforms are increasingly prescribing GLP-1 receptor agonists off-label for substance use disorder treatment, outpacing formal FDA approval for these indications. Clinical experts have raised concerns about fragmented care models and the potential exposure of patients to insufficiently studied risks in this context. The trend highlights growing tension between rapid digital health adoption and the regulatory frameworks designed to ensure patient safety in peptide-based therapeutics.

GLP-1 · Semaglutide · Tirzepatide

Big trials push beyond obesity to see if GLP-1s can quell alcohol, drug cravings

Major clinical trials are now investigating whether GLP-1 receptor agonists can reduce cravings for alcohol and addictive substances, expanding the therapeutic scope of this drug class well beyond metabolic disease. Researchers are examining the neurological mechanisms by which GLP-1 compounds may modulate reward pathways associated with addiction. The findings could represent a significant new frontier for peptide-based therapies and reshape treatment paradigms for substance use disorders.

GLP-1 · Semaglutide · Tirzepatide

Ultrasounds for Schizophrenia; 'Circadian' Depression; GLP-1s and Eating Disorders

This roundup briefly references GLP-1 receptor agonists in the context of eating disorders, representing one item among several unrelated psychiatry topics. The inclusion highlights growing clinical interest in GLP-1 therapies beyond metabolic indications, with researchers examining their potential effects on appetite regulation and compulsive eating behaviors. The coverage remains preliminary and is presented alongside unrelated neurological research.

GLP-1

1 in 4 Army Men Have Low T; GLP-1 in Menopause; Retatrutide Side Effects on Reddit

A MedPage Today roundup highlights new research showing that nearly half of American women ages 40 to 60 report menopausal symptoms, with GLP-1 receptor agonists emerging as a discussed intervention in that population. The digest also covers patient-reported side effect experiences with retatrutide circulating on social media platforms, reflecting growing public engagement with incretin-based peptide therapies. These data points collectively illustrate the expanding clinical and consumer conversation surrounding GLP-1 class compounds.

Retatrutide · GLP-1

Lilly's retatrutide creeps closer to market for sleep apnea

Eli Lilly is advancing retatrutide, its triple agonist targeting GLP-1, GIP, and glucagon receptors, toward regulatory submission for obstructive sleep apnea following promising clinical trial data. The company is building a multi-indication strategy around the peptide, with an obesity launch anticipated in the near term and additional therapeutic areas in development. Industry analysts describe heightened market expectations for retatrutide as competition among incretin therapies continues to intensify.

Retatrutide · GLP-1 · GIP

Another Incretin Drug Proves Mettle in Sleep Apnea

Two parallel randomized clinical trials demonstrated that retatrutide, a novel GLP-1/GIP/glucagon triple receptor agonist, significantly reduced obstructive sleep apnea severity in adults with obesity or overweight, regardless of type 2 diabetes status. The findings add to a growing body of evidence supporting incretin-based therapies as treatment options beyond glycemic control and weight loss. Researchers view the results as a meaningful expansion of the therapeutic applications for this class of peptide drugs.

Retatrutide · GLP-1 · GIP

STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole

A bipartisan coalition of lawmakers has formally urged the FDA to address a regulatory loophole currently being exploited to import unauthorized compounded versions of retatrutide, Eli Lilly's investigational obesity peptide. The request centers on closing the pathway that allows knockoff formulations of the unapproved drug to enter the United States market outside of standard FDA oversight. The development signals growing congressional attention to peptide importation enforcement and the integrity of the drug approval process.

Retatrutide

STAT+: Pharmalittle: We're reading about an HHS peptide push, Trump's pharma stock holdings, and more

The Trump administration is moving forward with a plan to allow compounding pharmacies to produce certain peptides, a policy initiative being advanced through HHS and the FDA. This development is part of a broader effort to expand patient access to compounded therapies that have faced scheduling and regulatory restrictions in recent years. Industry stakeholders are monitoring the progress of this policy as it advances toward formal rulemaking.

Spontaneous Abortion Risk Higher With Some Migraine Drugs, U.S. Study Shows

A retrospective U.S. study involving more than 7,100 pregnant women found that early pregnancy exposure to anti-CGRP monoclonal antibodies was associated with an elevated risk of spontaneous abortion. The findings raise important safety considerations for the use of calcitonin gene-related peptide pathway therapies in women of childbearing age. Clinicians prescribing CGRP-targeting agents for migraine prevention are advised to review these data in the context of patient counseling.

CGRP

CHMP endorses Eli Lilly's GLP-1 pill and three other new drugs

The European Medicines Agency's Committee for Human Medicinal Products has endorsed orforglipron, Eli Lilly's oral GLP-1 receptor agonist, representing a major milestone in the race to bring non-injectable weight management therapies to market. The approval recommendation positions Lilly to compete directly with Novo Nordisk's oral semaglutide offering in the European market. This development signals continued momentum in the oral small-molecule GLP-1 space and may have implications for global prescribing patterns and compounding demand.

Orforglipron · GLP-1 · Semaglutide

FDA considers interim access for compounded peptides; Enspryng's label expansion

The FDA and HHS have submitted an interim access policy for compounding using certain peptides to the White House Office of Information and Regulatory Affairs for review, marking a significant potential shift in how compounded peptides are regulated and accessed. The proposed policy could open pathways for compounding pharmacies to legally produce specific peptide compounds that have faced regulatory uncertainty in recent years. Providers and compounding pharmacies are closely watching this development as it moves through the federal review process.

Hospitals' next lucrative bet — longevity clinics

Major hospital systems are increasingly investing in longevity clinics as a high-margin service line, reflecting broader consumer demand for proactive health optimization. The STAT News podcast examines the business and clinical forces driving this expansion into preventive and regenerative medicine. Peptide therapies and other longevity-focused treatments are central to many of these emerging clinic models.

Trump Administration Advances Plan for Peptides Favored by RFK Jr.

U.S. health officials are moving forward with a framework to allow specialty pharmacies to produce certain peptide compounds, marking a notable shift in the regulatory landscape surrounding these widely used injectable therapies. The initiative has gained public visibility in part due to Health Secretary Robert F. Kennedy Jr.'s vocal support for peptide-based treatments, which have seen surging demand among wellness and longevity-focused patients. The policy development is poised to reshape compounding pharmacy access to peptides and may establish clearer guidelines for an industry that has long operated without formal federal oversight.

Trump administration advances plan for peptide drugs favored by RFK Jr.

U.S. health officials are actively advancing a regulatory framework that would permit specialty pharmacies to compound and dispense certain peptide therapies, a category of injectable substances that has grown substantially in popularity but has operated in a largely unregulated space. The plan, which has drawn attention due to Health Secretary Robert F. Kennedy Jr.'s public support for peptide therapies, represents a significant policy shift in how compounding pharmacies may access and produce these compounds. The outcome of this regulatory effort is expected to have broad implications for providers, patients, and the compounding pharmacy industry.

Making SIRT1 and NAD+ Therapies Work in People

Researchers publishing in Biology have examined SIRT1 functional reserve as a key dimension of biological aging, detailing how its depletion contributes to age-related decline and how NAD+ precursor therapies may help restore activity. The review maps the translational challenges of moving SIRT1 and NAD+ interventions from animal models into effective human protocols. This work carries direct relevance for longevity clinicians exploring adjunct peptide and metabolic optimization strategies.

Oral Peptide Shows Durable Efficacy in Ulcerative Colitis

Results from the phase IIb ANTHEM-UC trial demonstrate that an oral peptide blocking the interleukin-23 receptor provides durable long-term efficacy in patients with moderately to severely active ulcerative colitis. The findings represent a meaningful advance in peptide-based therapeutics for inflammatory bowel disease, highlighting the growing clinical viability of orally administered peptide compounds. This trial adds to mounting evidence that peptide therapies can achieve sustained disease control in chronic immune-mediated conditions.

miR-128-3p Inhibition Improves Muscle Mass and Function in Aged Mice

Researchers have identified miR-128-3p as a targetable microRNA whose inhibition produces meaningful improvements in muscle mass and function in aged mice, offering a potential therapeutic strategy to counteract age-related sarcopenia. The work by Elenae Therapeutics is partly contextualized by growing concern over muscle loss induced by GLP-1 receptor agonists, which has accelerated funding interest in muscle-preserving interventions. The findings hold dual relevance for patients on GLP-1 therapy and for the broader longevity and healthy aging research community.

GLP-1

Yes, GLP-1s Are Changing What Food People Buy — Here's How

New consumer data indicates that individuals using GLP-1 receptor agonists are making measurably different food purchasing decisions compared to those not on these medications. The findings suggest the behavioral and appetite-modifying effects of GLP-1 therapies extend into real-world dietary patterns beyond clinical settings. Researchers and industry observers are increasingly examining these downstream lifestyle shifts as part of the broader health impact profile of GLP-1 agents.

GLP-1

New study examines GLP-1 impact on interactions with criminal justice system, employment, housing stability

A newly announced clinical trial is investigating whether GLP-1 receptor agonists can produce measurable improvements in social determinants of health, including criminal justice involvement, employment outcomes, and housing stability. The research builds on a growing body of evidence suggesting these agents may reduce substance use disorder behaviors, potentially extending their therapeutic impact well beyond metabolic disease. The trial represents a significant expansion of the clinical scope being attributed to GLP-1 class medications.

GLP-1

Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump

Biomea Fusion's oral GLP-1 candidate drew significant market attention after clinical data disappointed investors, resulting in a notable stock decline. The development highlights the competitive pressure facing next-generation oral GLP-1 formulations as the broader receptor agonist space continues to attract substantial pharmaceutical investment. This industry roundup underscores the financial stakes surrounding emerging GLP-1 pipeline assets.

GLP-1

No Effect of GLP-1s on Anti-VEGF Injection Frequency for Diabetic Macular Edema

A large retrospective cohort study presented in New Orleans found that GLP-1 receptor agonists did not significantly alter anti-VEGF treatment frequency in patients with diabetic macular edema over a 24-month follow-up period. The findings provide important clarifying data for clinicians managing patients with comorbid diabetes and retinal disease who are also receiving GLP-1 based therapies. While the study does not diminish the metabolic benefits of GLP-1 receptor agonists, it suggests limited ophthalmologic crossover efficacy in this specific context.

GLP-1

Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued

Two deaths linked to counterfeit versions of retatrutide, an investigational triple receptor agonist weight-loss compound, have been reported to the FDA, raising urgent safety concerns around illicit peptide manufacturing. The reports underscore the public health risks associated with unregulated compounding and black-market distribution of unapproved peptide therapies. Ongoing litigation alleging severe adverse events from GLP-1 receptor agonists adds further regulatory and clinical scrutiny to this drug class.

Retatrutide · GLP-1

Second Century Foundation Launches to Advocate for Longevity Research

The Second Century Foundation, a newly established 501(c)(3) private operating foundation, has launched with a mission to accelerate breakthroughs in human longevity research and development. The organization adds to a growing ecosystem of non-profit advocates working to increase funding directed at treating aging as a medical condition. Its formation reflects continued momentum within the longevity industry to attract both philanthropic and investment capital toward aging research.

Verdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'

Verdiva Bio has terminated a Phase 2 trial of its oral GLP-1 candidate, citing shifting market conditions in the competitive obesity therapeutics landscape. The decision highlights growing pressure on pipeline-stage companies as established GLP-1 receptor agonists continue to dominate the market. The move raises questions about the commercial viability of next-generation oral formulations competing against entrenched injectable and oral offerings from larger pharmaceutical players.

GLP-1

New injection makes fat cells self-destruct

Scientists have developed an experimental injectable compound capable of selectively destroying adipocytes and substantially reducing visceral fat accumulation in early study models. The research also suggests the approach may help mitigate the weight regain commonly observed after discontinuation of GLP-1 receptor agonists such as semaglutide. If validated in further trials, the therapy could represent a complementary or alternative strategy to existing peptide-based obesity treatments.

Semaglutide · GLP-1

Popular weight loss drugs linked to a surprising fingernail problem

New research has identified unexpectedly elevated rates of nail detachment, hair loss, and scalp inflammation among users of GLP-1 receptor agonists such as semaglutide and liraglutide. Investigators determined that weight loss alone does not fully account for the observed differences in adverse dermatological events, pointing to potential direct drug effects. The findings draw attention to a class of underreported side effects that clinicians and patients should monitor during GLP-1 therapy.

Semaglutide · GLP-1

Ongoing lawsuits allege GLP-1s can cause serious harm. But we don't know how often

A growing wave of litigation against GLP-1 receptor agonist manufacturers highlights a critical gap in post-market surveillance data regarding serious adverse events such as vision loss and pancreatitis. The scarcity of robust pharmacovigilance information is complicating both scientific assessment and legal proceedings surrounding drugs like semaglutide and tirzepatide. Researchers and regulators face mounting pressure to establish clearer reporting mechanisms as the patient population using these therapies continues to expand rapidly.

GLP-1 · Semaglutide · Tirzepatide

The Doctor-Approved Plan for Taking a GLP-1 Without Losing Your Muscle

As GLP-1 receptor agonist use continues to rise, clinicians are raising concerns about the accompanying loss of lean muscle mass in patients undergoing weight loss treatment. This article outlines a physician-reviewed framework for preserving muscle during GLP-1 therapy through targeted nutrition and resistance training strategies. The guidance reflects a growing clinical conversation around optimizing body composition outcomes alongside pharmacological intervention.

GLP-1 · Semaglutide · Tirzepatide

Taking GLP-1s Was Linked To 18% Lower Risk Of This Eye Condition

New research has identified an association between GLP-1 receptor agonist use and an 18 percent reduction in the risk of a specific ocular condition, adding to the expanding list of pleiotropic benefits being observed in clinical and epidemiological data. The finding reinforces the view that GLP-1 pathways interact with a broader range of physiological systems than originally understood. Researchers note that further investigation will be needed to establish the mechanistic basis of the observed protective effect.

GLP-1 · Semaglutide · Tirzepatide

What GLP-1s Are Actually Doing For Blood Pressure, From 43K+ Adults

A large-scale analysis encompassing more than 43,000 adults has found that GLP-1 receptor agonists produce meaningful cardiovascular benefits beyond weight reduction, with notable effects on blood pressure outcomes. The scope of the dataset lends considerable statistical weight to findings that researchers say extend the therapeutic profile of this drug class. The study adds to a growing body of evidence positioning GLP-1 therapies as broad cardiometabolic agents rather than strictly weight loss medications.

GLP-1 · Semaglutide · Tirzepatide

WHO advises against obesity drugs for younger children

The World Health Organization has issued guidance recommending that GLP-1 receptor agonists not be prescribed to children under age 10 for obesity treatment, while advising that adolescents ages 10 to 19 should only receive these therapies after supervised lifestyle interventions have failed. The guidance introduces a significant new layer of global regulatory framing around pediatric use of GLP-1 drugs. This development is likely to influence prescribing standards and regulatory postures in markets worldwide.

GLP-1 · Semaglutide · Tirzepatide

Squats and Planks for BP Lowering; DCBs Compared Head to Head; GLP-1s for HFpEF?

This clinical roundup raises the emerging question of whether GLP-1 receptor agonists may offer therapeutic benefit for patients with heart failure with preserved ejection fraction, a condition with limited treatment options. The inclusion of GLP-1s in a cardiovascular context reflects the expanding body of evidence supporting their role beyond metabolic disease management. Clinicians and researchers are increasingly attentive to the cardiometabolic crossover potential of this drug class.

GLP-1

Menopause Tracking Wearables; Teen GLP-1 Prescribing; Iatrogenic Menopause Risks

A new analysis highlights a substantial surge in GLP-1 medication prescribing among bariatric surgery-eligible adolescents between 2017 and 2025, with nine out of ten eligible teens still not receiving treatment. The findings underscore both the growing clinical acceptance of GLP-1 receptor agonists in younger populations and the significant gap in therapeutic reach. This trend carries notable implications for prescribing practices, access equity, and long-term outcomes research in pediatric metabolic care.

GLP-1

Declining Autophagy Impairs Senescent Cell Clearance

New research demonstrates that age-related decline in autophagy directly compromises the immune system's ability to clear senescent cells, accelerating hallmarks of biological aging. Activating the autophagy pathway was shown to reduce measurable signs of cellular senescence, pointing toward a targetable mechanism for longevity interventions. These findings are relevant to peptide researchers investigating compounds that modulate autophagy and cellular repair pathways.

STAT+: Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals

Major nonprofit hospitals are entering the longevity medicine space, offering personalized health optimization programs at price points ranging from $5,500 to $45,000 annually. These clinics represent a growing institutional recognition of preventive and longevity-focused care, a sector that increasingly intersects with peptide and hormone-based therapies. The expansion signals broader mainstream adoption of longevity medicine frameworks that have long been central to peptide therapy practice.

STAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen

Advocates for stem cell treatments are drawing direct comparisons to the regulatory pathway that peptides navigated under the MAHA movement, hoping to achieve similar FDA legitimacy. The article examines how peptides gained formal recognition at the FDA and whether that precedent can be applied to stem cell therapies. This piece offers substantive context on the political and regulatory environment that shaped peptide legitimacy under the current administration.

Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes

A phase III clinical trial evaluating retatrutide, an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, demonstrated substantial improvements in both glycemic control and body weight among 1,152 adults with obesity and type 2 diabetes. The findings represent a significant milestone for next-generation receptor agonist therapies moving through late-stage development. Results position retatrutide as a compelling candidate in the expanding landscape of peptide-based metabolic treatments.

Retatrutide · GLP-1 · GIP

#EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy

At the European Association for the Study of Diabetes 2026 conference, Regeneron presented a strategy for differentiating its obesity candidate by combining it with lipid-lowering therapy, as competition in the GLP-1 space intensifies. The approach reflects broader industry efforts to find clinical advantage beyond weight loss efficacy alone as late-stage GLP-1 trials continue to post strong results. The combination strategy could reshape how next-generation obesity therapeutics are developed and positioned commercially.

GLP-1

FDA Leaders Name Longevity a Priority at ARDD

Senior FDA officials announced at the Aging Research and Drug Discovery meeting in Boston that the agency intends to formally incorporate aging into its regulatory science agenda. The announcement signals a potentially transformative shift in how longevity therapies, including peptide-based interventions, could navigate a pathway toward regulatory approval. This development is closely watched by researchers and clinicians working on peptide therapies targeting age-related decline.

STAT+: Lilly bypasses Australian pharmacies with DTC model

Eli Lilly is expanding its direct-to-consumer LillyDirect platform to Australia, allowing patients to receive Mounjaro (tirzepatide) without going through traditional pharmacy channels. The move represents a significant shift in how GLP-1 and GIP receptor agonist therapies are distributed internationally, cutting out intermediary dispensing relationships. Australian physicians and pharmacists have expressed concern over the model's implications for patient oversight and the broader compounding pharmacy landscape.

Tirzepatide · GLP-1 · GIP

Opinion: I studied GLP-1 use in children. The results are reassuring

A transplant surgeon shares findings from research into GLP-1 receptor agonist use in pediatric populations, reporting reassuring safety and efficacy signals that support earlier intervention in childhood obesity. The author argues that treating obesity in childhood may prevent decades of irreversible metabolic and organ damage. The opinion adds to a growing body of evidence informing clinical guidelines on GLP-1 therapy in younger patients.

GLP-1

Nurse Choked With Stethoscope; $15M Award for Blinded Patient; Fake Ozempic Charges

A news roundup includes a report of criminal charges related to the distribution of counterfeit Ozempic, highlighting ongoing enforcement concerns surrounding the authenticity of GLP-1 receptor agonist products in the marketplace. The case is part of a broader pattern of fraud and counterfeiting activity that regulators and law enforcement have increasingly targeted as demand for GLP-1 medications has surged. Providers and patients are reminded to source medications only through verified, licensed channels.

Semaglutide · GLP-1

More New Moms Are Starting GLP-1 Drugs

An analysis of insurance claims data reveals that postpartum initiation of GLP-1 receptor agonists has increased more than twentyfold, reflecting a substantial shift in prescribing patterns among new mothers within six months of delivery. The trend raises important questions about safety, appropriateness, and long-term outcomes for this population. Healthcare providers and researchers are calling for dedicated studies to better characterize risks and benefits in the postpartum period.

GLP-1

Novel GIP/GLP-1 Yields Uneven Findings in Diabetes Patients With Obesity

The phase III SYNCHRONIZE-2 trial evaluating an investigational dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes and obesity reported modest weight loss results alongside notable tolerability concerns at tested doses of 3.6 mg and 6 mg. The mixed findings underscore the challenge of optimizing dual agonist therapies for both efficacy and patient tolerability. These results will inform ongoing development strategies for next-generation incretin-based peptide therapies.

GLP-1 · GIP

GLP-1s Tied to Detached Fingernails in New Study

A large prospective study has identified a significant association between GLP-1 receptor agonist use and nail disorders, with affected patients showing up to a fourfold higher likelihood of developing onycholysis compared to non-users. The findings contribute to the evolving understanding of dermatological side effects linked to this class of drugs. Clinicians prescribing GLP-1 therapies are encouraged to monitor patients for nail-related adverse events.

GLP-1

Striking Weight Loss Seen With Combo Drug in Diabetes Trial

A phase IIb trial evaluating eloralintide combined with tirzepatide in adults with type 2 diabetes demonstrated impressive weight loss outcomes across a 10-arm study design. The findings highlight the growing interest in combination peptide-based therapies targeting both metabolic and weight-related endpoints. Researchers and clinicians are watching closely as dual and multi-agonist approaches continue to advance through clinical development.

Tirzepatide · Eloralintide · GLP-1 · GIP

The Drive to Class GLP-1 Receptor Agonists as Geroprotective Drugs

Fight Aging examines the growing push within academic and pharmaceutical circles to reframe GLP-1 receptor agonists as geroprotective or anti-aging agents rather than purely metabolic drugs. The analysis argues that much of the observed longevity-associated benefit may be attributable to caloric restriction induced by the drugs rather than direct geroprotective mechanisms. The piece offers a measured critique of industry-driven publication trends and calls for rigorous separation of mechanistic claims from downstream metabolic effects.

GLP-1